Abstract: The present invention relates to an antibody variable domain, which specifically binds to IL-31, to multispecific antibodies comprising one or two of said antibody variable domains and at least one further binding domain that specifically binds to a target different from IL-31. The present invention further relates to a nucleic acid or two nucleic acids encoding said antibody variable domain or said multispecific antibody, vector(s) comprising said nucleic acids or said nucleic acids, host cell(s) comprising said nucleic acid or said nucleic acids or said vector(s), and a method of producing said antibody variable domain or said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said antibody variable domain or said multispecific antibody and to methods of use thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising a first multispecific antibody (MA1) comprising one binding domain, which specifically binds to CD137 (CD137-BD), and one binding domain, which specifically binds to PDL1 (PDL1-BD); a second multispecific antibody (MA2) comprising at least one binding domain, which specifically binds to a tumor cell associated antigen (TAA-BD), and one binding domain, which specifically binds to CD3 (CD3-BD); and a pharmaceutically acceptable carrier. The present invention further relates to a kit comprising said first multispecific antibody MAl and said second multispecific antibody MA2. The present invention further relates to the use as well as to methods of use of said pharmaceutical composition or said kit.

Abstract: The present invention relates to a multispecific antibody comprising two antibody-based binding domains, which specifically binds to mesothelin (MSLN-BD); and at least one antibody-based binding domain, which specifically binds to CD3 (CD3-BD); wherein said multispecific antibody does not comprise an immunoglobulin Fc region polypeptide, and wherein each of said MSLN-BD binds to mesothelin (MSLN) with a monovalent dissociation constant (KD) in the range of from 0.5 to 20 nM, when measured by SPR. The present invention further relates to nucleic acid sequence(s) encoding said multispecific antibody, vector(s) comprising aid nucleic acid sequence(s), host cell(s) comprising said nucleic acid sequence(s) or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.

Abstract: The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to a multispecific antibody comprising at least one domain specifically binding to a tumor-associated immune checkpoint antigen with low affinity, and at least one domain specifically binding to a tumor-associated antigen (TAA), and pharmaceutical compositions and methods of use thereof.

Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.

Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.

Abstract: The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to an isolated antibody which specifically binds human PDL 1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: This invention relates to novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned tandem on two separate protein chains, respectively.

Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.

Abstract: The invention relates to a receiver of very high frequency band signals transmitted by a transmitter, comprising an antenna, a band-pass filter, a software-defined radio adapted to receive the signals filtered by said band-pass filter via a first input and to digitise said signals with a predetermined sampling rate in a predetermined sampling frequency band so as to obtain a digitised signal, characterised in that the receiver comprises at least two extraction modules each capable of receiving the digitised signal and of extracting part of the digitised signal, referred to as extracted signal, in a natural frequency channel, and at least two demodulators each capable of receiving an extracted signal and of demodulating said signal so as to retrieve data. The invention further relates to a very high frequency signals transmitter and to a corresponding transmission method.

Abstract: A method for geo-locating the raw data exchanged between an aircraft and a VHF receiver is provided. Each item of raw data includes an identifier of the aircraft transmitting this item of data. The method includes obtaining position data of the aircraft. In this regard, the position data includes a piece of information which represents the identifier of the aircraft. The method also includes correlating the raw data and the position data by determining the data that has an identical identifier.

Abstract: A process for the automatic searching by an aircraft for a communication address of a ground entity of an ATN network. In the process, each address is coded according to a hierarchical binary tree structure including several fields. A first field identifies the network and the subsequent fields identify entities of the network. The process determines in the aircraft the address of the communication center to be contacted from the identity of an ground router which it receives, by comparing the received address of the router with those of the addresses contained in a database of the aircraft, and retaining as an address that which has the largest number of characters in common with the address of the ground router, given the tree structure of the addresses. Such a process may find particular application to ATN communications.